The global microbiome therapeutics market size is expected to reach $2,036.4 million by 2030, growing at a CAGR of 23.1% from 2021 to 2030. Growth is predicted to be fueled by the increasing prevalence of target disorders such as gastrointestinal (GI) illnesses, diabetes, and immunological indications. The domain is also fueled by the expanding strategic efforts to create microbiome therapeutics, the potential of these products to fill gaps in current treatment options, and their promise to be a safer alternative to traditional medication therapies.
Increasing Cases of Gastrointestinal and Infectious Diseases Boost the Industry Growth
GI problems are the main indication in clinical trials, where the use of microbiome therapies is being actively researched. Inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis are the three conditions that are the focus of the majority of companies that provide medicines for GI illnesses. Thus, the increasing prevalence of gastrointestinal and infectious diseases is expected to drive the market at a significant growth rate.
Regional Analysis
The North American microbiome therapeutics market accounted for the largest revenue share, of more than 39%, in 2021. This is because one of the world's most advanced healthcare systems is found in North America, its developed economy, and the healthcare industry has seen significant funding and investment. Moreover, the demand for microbiome treatments is increasing in the region, as a result of the rising prevalence of illnesses like IBD, colon cancer, and Crohn's disease as well as surging awareness of safer treatment options, and improving healthcare screenings and protocols.
In addition, Europe is at the forefront of research in microbiome therapies, as it encourages the emergence of new biotechnology businesses creating microbiome-based products. France, Germany, the U.K., Sweden, Spain, and Italy are among the top European nations, where microbiome medicinal items are being widely used. The industry domination in these nations is mostly because of the expanding government and private sectors’ investments in microbiome therapeutic research as well as the increasing awareness of the therapeutic potential of these products.
On the other hand, the APAC market is projected to witness the fastest growth in the coming years. A major force behind research in the microbiome therapeutics sector in the region has been the mutual cooperation between scientists of APAC and labs in North America and Europe. Such intraregional partnerships have also paved the way for the development of cutting-edge therapeutic approaches. Moreover, one of the most alluring prospects for investments in the biopharmaceutical industry is microbiome therapies.
Strategic Developments in Market
Major firms in the global industry are conducting in-depth research to have an advantage over rivals. The businesses are working hard to create and manufacture goods for therapeutic use. Also, they have been involved in funding activities to improve their position. For instance:
- In March 2022, Microbiotica revealed that its Series B round of funding collected $67 million (GBP 50 million). The money will be used by Microbiotica to advance the clinical development of oral live biotherapeutics.
- In April 2021, the Patient Advisory Board (PAB) was created by 4D pharma plc in partnership with Parkinson's UK, a nonprofit organization. The PAB will help 4D pharma plc collect patient-centric opinions and improve awareness of current therapies and related challenges.
Major players in the market are 4D pharma plc, Seres Therapeutics Inc., SANOFI S.A., Enterome, Destiny Pharma Plc, Taisho Pharmaceutical Holdings Co. Ltd., AOBiome LLC, Ferring International Center S.A., Pendulum Therapeutics Inc., and YSOPIA Bioscience.